Gyre Therapeutics (GYRE) Competitors $8.14 +0.34 (+4.36%) As of 07/3/2025 03:26 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GYRE vs. KYMR, VKTX, MOR, CRNX, ALVO, MLTX, CPRX, IMVT, HCM, and OGNShould you be buying Gyre Therapeutics stock or one of its competitors? The main competitors of Gyre Therapeutics include Kymera Therapeutics (KYMR), Viking Therapeutics (VKTX), MorphoSys (MOR), Crinetics Pharmaceuticals (CRNX), Alvotech (ALVO), MoonLake Immunotherapeutics (MLTX), Catalyst Pharmaceuticals (CPRX), Immunovant (IMVT), HUTCHMED (HCM), and Organon & Co. (OGN). These companies are all part of the "pharmaceutical products" industry. Gyre Therapeutics vs. Its Competitors Kymera Therapeutics Viking Therapeutics MorphoSys Crinetics Pharmaceuticals Alvotech MoonLake Immunotherapeutics Catalyst Pharmaceuticals Immunovant HUTCHMED Organon & Co. Kymera Therapeutics (NASDAQ:KYMR) and Gyre Therapeutics (NASDAQ:GYRE) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, risk and institutional ownership. Which has more volatility and risk, KYMR or GYRE? Kymera Therapeutics has a beta of 2.18, indicating that its share price is 118% more volatile than the S&P 500. Comparatively, Gyre Therapeutics has a beta of 1.72, indicating that its share price is 72% more volatile than the S&P 500. Which has higher earnings and valuation, KYMR or GYRE? Gyre Therapeutics has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Gyre Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKymera Therapeutics$47.07M61.99-$223.86M-$3.10-14.45Gyre Therapeutics$105.76M7.22$12.09M$0.02407.00 Do insiders and institutionals have more ownership in KYMR or GYRE? 24.0% of Gyre Therapeutics shares are held by institutional investors. 16.0% of Kymera Therapeutics shares are held by company insiders. Comparatively, 10.0% of Gyre Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media favor KYMR or GYRE? In the previous week, Kymera Therapeutics had 23 more articles in the media than Gyre Therapeutics. MarketBeat recorded 24 mentions for Kymera Therapeutics and 1 mentions for Gyre Therapeutics. Kymera Therapeutics' average media sentiment score of 0.46 beat Gyre Therapeutics' score of 0.00 indicating that Kymera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Gyre Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is KYMR or GYRE more profitable? Gyre Therapeutics has a net margin of 7.20% compared to Kymera Therapeutics' net margin of -409.07%. Gyre Therapeutics' return on equity of 9.73% beat Kymera Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Kymera Therapeutics-409.07% -30.11% -25.65% Gyre Therapeutics 7.20%9.73%7.66% Do analysts recommend KYMR or GYRE? Kymera Therapeutics presently has a consensus price target of $59.11, indicating a potential upside of 31.91%. Given Kymera Therapeutics' higher possible upside, equities analysts clearly believe Kymera Therapeutics is more favorable than Gyre Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kymera Therapeutics 0 Sell rating(s) 1 Hold rating(s) 17 Buy rating(s) 1 Strong Buy rating(s) 3.00Gyre Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryKymera Therapeutics and Gyre Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get Gyre Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GYRE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GYRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GYRE vs. The Competition Export to ExcelMetricGyre TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$762.25M$2.91B$5.53B$9.05BDividend YieldN/A2.44%5.24%4.03%P/E Ratio407.2021.5627.5220.22Price / Sales7.22281.76421.02118.64Price / Cash41.1742.7336.8958.07Price / Book7.757.518.045.67Net Income$12.09M-$55.05M$3.18B$249.13M7 Day Performance9.70%4.61%2.90%3.28%1 Month Performance2.13%4.72%3.70%5.55%1 Year Performance-34.51%5.92%36.15%21.12% Gyre Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GYREGyre Therapeutics0.0826 of 5 stars$8.14+4.4%N/A-30.5%$762.25M$105.76M407.2040KYMRKymera Therapeutics3.1715 of 5 stars$46.29+0.9%$59.82+29.2%+48.6%$2.99B$58.89M-14.93170Analyst ForecastInsider TradeVKTXViking Therapeutics4.3593 of 5 stars$24.86-4.4%$87.15+250.6%-44.2%$2.92BN/A-21.6220Trending NewsInsider TradeMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730News CoverageCRNXCrinetics Pharmaceuticals3.5532 of 5 stars$29.91-0.8%$74.56+149.3%-32.4%$2.82B$1.04M-7.83210ALVOAlvotech3.5174 of 5 stars$9.13-2.4%$18.00+97.2%-24.4%$2.82B$491.98M24.681,032MLTXMoonLake Immunotherapeutics2.1799 of 5 stars$44.87+3.1%$78.71+75.4%+9.9%$2.78BN/A-19.512News CoverageCPRXCatalyst Pharmaceuticals4.9243 of 5 stars$22.12-1.6%$32.83+48.4%+41.3%$2.74B$491.73M14.0980IMVTImmunovant1.5582 of 5 stars$15.47-2.1%$38.33+147.8%-35.9%$2.70BN/A-5.65120HCMHUTCHMED1.8163 of 5 stars$15.21+2.5%$19.00+24.9%-9.3%$2.59B$630.20M0.001,811Positive NewsGap UpOGNOrganon & Co.4.8946 of 5 stars$9.82+0.7%$18.00+83.3%-50.4%$2.53B$6.40B3.414,000Trending News Related Companies and Tools Related Companies Kymera Therapeutics Competitors Viking Therapeutics Competitors MorphoSys Competitors Crinetics Pharmaceuticals Competitors Alvotech Competitors MoonLake Immunotherapeutics Competitors Catalyst Pharmaceuticals Competitors Immunovant Competitors HUTCHMED Competitors Organon & Co. Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GYRE) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe mainstream media is wrong about AI — againThe mainstream media got it wrong … yet again. AI has recently turned the tech world on its head. And th...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gyre Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gyre Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
